Home
>
US Stocks
>
Aeglea BioTherapeutics Inc
Aeglea BioTherapeutics Inc
AGLE

Aeglea BioTherapeutics Inc (AGLE)

$7.33.55%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
7.4
Today Low/High
7.07 / 7.4
52 Week Low/High
$5.82 / $9.9
Market Cap
$319.9M

Company Details

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families.
Organisation
Aeglea BioTherapeutics Inc
Employees
90
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Aeglea BioTherapeutics Inc (AGLE) share price today?

Can Indians buy Aeglea BioTherapeutics Inc (AGLE) shares?

How can I buy Aeglea BioTherapeutics Inc (AGLE) shares from India?

Can Fractional shares of Aeglea BioTherapeutics Inc (AGLE) be purchased?

What are the documents required to start investing in Aeglea BioTherapeutics Inc (AGLE) stocks?

We are a SEBI registered investement advisor